Bulletin
Investor Alert

The Wall Street Journal Archives | Email alerts

Sept. 28, 2021, 3:20 a.m. EDT

Merck nears deal for rare-disease-drug maker Acceleron

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Acceleron Pharma Inc. (XLRN)
  • X
    Bristol Myers Squibb Co. (BMY)

or Cancel Already have a watchlist? Log In

By Cara Lombardo and Ben Dummett

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.

The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.

Should a deal come together, it would be one of Merck’s /zigman2/quotes/209956077/composite MRK 0.00% biggest and represent a bet on the treatments for the respiratory and blood diseases that Acceleron /zigman2/quotes/203395072/composite XLRN +0.50% specializes in.

Merck appears to have beaten out other potential suitors for Acceleron including Bristol Myers Squibb Co., /zigman2/quotes/202559280/composite BMY +1.14% which already owns a big stake in the company.

An expanded version of this story is available at WSJ.com

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 78.33
0.00 0.00%
Volume: 12.87M
Oct. 15, 2021 4:02p
P/E Ratio
35.76
Dividend Yield
3.32%
Market Cap
$198.28 billion
Rev. per Employee
$648,824
loading...
/zigman2/quotes/203395072/composite
US : U.S.: Nasdaq
$ 172.94
+0.86 +0.50%
Volume: 408,525
Oct. 15, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$10.57 billion
Rev. per Employee
$296,548
loading...
/zigman2/quotes/202559280/composite
US : U.S.: NYSE
$ 58.36
+0.66 +1.14%
Volume: 9.45M
Oct. 15, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
3.36%
Market Cap
$129.68 billion
Rev. per Employee
$1.41M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.